EGFR and neoplasm: On the other hand, panitumumab has shown less clinical efficacy than cetuximab (Mesia et al., 2015), this result may be explained by a less potent NK cell activation induced by panitumumab given its IgG2 framework, furthermore, its monocyte activation capability may be innocuous to EGFR expressing tumor targets given that monocytes are not capable of mediating ADCC.